Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will...
Year: 2025
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics...
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the...
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company...
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™...
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the...
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
CHATHAM, N.J., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated...
Grow Up Conference & Expo Debuts in Vancouver
B2B cannabis event returns to B.C. for three days of education and business-building Brands & Buyers Zone Connect with retail...
Humber River Health Achieves Excellent Scores, Remarkably Low Rate of Patient Harm, Leading Provincial and National Benchmarks
Humber River Hospital Humber River Health’s hospital harm rates in comparison to the provincial and national averages. Data provided by...
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Event to be held October 14th at 4 p.m. ESTBETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc....
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era...
Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income
Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net...
Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio
World-renowned longevity physician to help guide Klothea Bio as it prepares for a Phase 1B clinical trial of its Klotho...
Genvor Restores Trading Status and Expands Global Collaborative Research Network
Woodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable...
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
ACTON, Mass. and YAMANASHI, Japan, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), a medical diagnostics...
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is...
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero’s Mission of Bringing Novel...
Human Appeal’s Pot of Gold Film to Air on EarthX Channel on October 18
BayView Entertainment to Bring Groundbreaking Documentary to Streaming and Broadcast Audiences Pot of Gold Film to Air on EarthX Channel...
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent...
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...